Generic Exclusivity Awards Process Might Go Public
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA wants to know whether 180-day exclusivity should be revealed up front; question is one of many on ANDA reviews to be considered at September public hearing.
You may also be interested in...
Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
U.S. FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
Generic Exclusivity? Who Cares! Industry Offers Few Opinions On Potential Changes
FDA officials still looking for input after transparency issue not widely addressed during GDUFA policy meeting.
ANDA Communication Complaints: FDA Takes Licking, Keeps Ticking
As sponsors vent about uncertain status of their ANDAs, FDA Office of Generic Drugs indicates number of ideas are in process, including providing target action dates for applications without formal review goals.